Hematologic Malignancies

UMGCC Experts Join Myeloproliferative Disorders Research Consortium

Ask the Expert

Get answers to your Myelodysplastic Syndromes questions.

Note: This is for informational purposes only. Doctors cannot provide a diagnosis or individual treatment advice via e-mail. Please consult your physician about your specific health care concerns.

Please install flash player to see this video.

Cancer Center Virtual Tour

Related Content

The University of Maryland Marlene and Stewart Greenebaum Cancer Center (UMGCC) has become a member of the Myeloproliferative Disorders Research Consortium, an international, multi-instssitutional non-profit consortium funded by the National Cancer Institute.

The consortium was set up to coordinate, facilitate, and perform basic and clinical research investigating the genetic and cellular mechanisms of Philadelphia chromosome negative myeloproliferative disorders.

Maria Baer, M.D., professor, Department of Medicine, and member of the Hematologic Malignancies Program at the Cancer Center, is the MPD-RC principal investigator at UMGCC. Ivana Gojo, M.D., associate professor, and Saul Yanovich, M.D., professor, Department of Medicine, are co-investigators.

Two MPD-RC clinical trials have been opened at the University of Maryland Greenebaum Cancer Center:

For more information on these and other clinical trials, please visit Clinical Trials at UMGCC.

For information about the clinical and research activities of the Hematologic Malignancies Program at UMGCC, please call 410-328-8708.

This page was last updated on: August 11, 2009.